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Whole body (WB) imaging plays an essential role in the
management of lymphoma patients, including defining
the full extent of the disease at baseline, allowing for an
accurate staging and therefore an adapted treatment
strategy, assessing treatment response and detecting
relapse. Contrast-enhanced computed tomography (CT)
has long been the imaging technique most commonly
used for staging and follow up of malignant lymphoma,
using International Working Group (IWG) criteria [1].
However, CT lacks functional and metabolic information,
compromising identification of disease in non-enlarged
lymph nodes or other organs, as well as sufficient contrast
in certain organs as for example the spleen or bone
marrow. In 2007, IWG response criteria were revised,
incorporating Positron Emission Tomography (PET) with
18-fluorodeoxyglucose (FDG) information [2], thus com-
bining metabolic information and anatomical data of the
CT resulting in a higher accuracy than the both imaging
modalities taken separately [3].
Diffusion Weighted Magnetic Resonance Imaging
(DW-MRI) probes noninvasively the random micro-
scopic motion of water molecules in the body, reflecting
cellularity and cell membrane integrity. Because of their
high cellularity and high nuclear-to-cytoplasm ratio,
lymphomas have a lower apparent diffusion coefficient
(ADC) than other tumors [4]. WB-DW-MRI allows both
anatomical information, as well as functional and quan-
titative evaluation of tumor sites, thanks to the extrac-
tion of the apparent diffusion coefficient (ADC). At
staging, lymphoma lesions have low ADC value except
necrotic areas.
Recent studies comparing whole-body DWI to PET-
CT have demonstrated the potential role of whole-body
DWI in routine lymphoma patient care but included
only a small number of patients. Using the DWIBS tech-
nique (diffusion weighted imaging with background
body signal suppression), Abdulqadhr et al. compared
whole-body DWI and PET/CT at staging with an agree-
ment in the Ann Arbor stage for 90.3% of patients [5].
Based on ADC analysis, Lin et al showed an agreement
at baseline in 93% of patients [4]. Response assessment
is necessary during therapy to readapt treatment strategy
if necessary, and to document a complete remission at
the end of treatment. After treatment, an increase in
ADC value of residual masses has been demonstrated
[6]. Recent technical breakthroughs in MRI technology
such as echo-planar imaging (EPI), high gradient ampli-
tudes, combined phased-array surface coils covering the
patient, and parallel imaging, have drastically improved
patient comfort and acceptance for whole body MRI
[7,8], making this technique feasible in clinical routine,
illustrating the need for radiologists to get familiar with
this technique. As a result, WB-DW-MRI with ADC
mapping has become a promising tool for lymphoma
staging and re-staging, and response assessment.
Based on our 4-years experience with WB-DW-MRI
applied in Hodgkin and diffuse large B-cell lymphoma
patients together with 18FDG-PET/CT, our objective is to
offer radiologists the information required to optimize
acquisition whole body DWI parameters on both 1.5 and
3T MR systems. We will expose the spectrum of imaging
findings and discuss the pitfalls, limitations, and potential
challenges of WB-DW-MRI in caring for lymphoma
patients.
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